Antiviral Agents against Omicron Subvariant BA.4.6 In Vitro

• Published in: The New England journal of medicine Vol. 388; no. 5; p. e12
• Main Authors: Walker, Jill, Schnell, Gretja, Kerr, William, Uraki, Ryuta, Imai, Masaki, Kawaoka, Yoshihiro
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 02.02.2023
• Subjects: ACE2; Angiotensin; Angiotensin-converting enzyme 2; Antiviral agents; Antiviral Agents - therapeutic use; Conflicts of interest; Humans; Monoclonal antibodies; Peptidyl-dipeptidase A; Severe acute respiratory syndrome coronavirus 2; United States > US; San Francisco California

To the Editor: Studies have shown that the neutralization activity of antibodies such as S309 (the precursor of sotrovimab) or sotrovimab, which bind outside the receptor-binding motif (RBM), depends on the expression level of the SARS-CoV-2 receptor (angiotensin-converting enzyme 2 [ACE2]), whereas...